Preliminary data from the COMPASS-IBD study showed an interdisciplinary care model improved psychosocial outcome values among patients with inflammatory bowel disease.
Author: Praveen Suthrum
Reported gastrointestinal (GI) outbreaks in England were halved during the first 6 months of the COVID-19 pandemic compared with a similar period over the 5 years’ prior, a retrospective ecological study found.
NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 3 study of etrasimod, an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator in development for the treatment of moderately to severely active ulcerative colitis (UC). In the study, etrasimod patients achieved statistically significant improvements in the primary endpoint of clinical remission at week 12 as compared with placebo. Statistically significant improvements were achieved in all key secondary endpoints in the trial as well. The safety profile was consistent with previous Phase 2 studies.
AGA and Practicing Clinicians Exchange (PCE®) are proud to collaborate on a new program designed specifically for the clinical needs of NPs and PAs in gastroenterology medicine, the 2022 Gastroenterology APP Bootcamp, which will take place Saturday, April 2, 2022, at 9 a.m. EDT.
March is National Colorectal Cancer (CRC) Awareness Month, a time aimed at raising awareness for what is the world’s second leading cause of cancer death worldwide. With pivotal clinical trials for new cancer blood tests – so-called ‘liquid biopsies’ – occurring in 2022, transformative change for the diagnostics surrounding CRC may be around the corner. Key developments in the CRC space have the potential to shape the rapidly evolving market around liquid biopsies.
Washington DC – Dr. Latha Alaparthi has been named president and chair of the board of directors of the Digestive Health Physicians Association (DHPA). Dr. Alaparthi and members of DHPA’s 13-member Executive Committee will lead DHPA’s health policy efforts to promote and preserve accessible, high quality and cost-efficient care in the independent gastroenterological medical practice setting.
Among patients with nonalcoholic fatty liver disease (NAFLD), the use of statins is associated with reduced cancer-related mortality, according to a study published in the Journal of Clinical Gastroenterology. Cardiovascular disease (CVD) is common among patients with NAFLD and is the leading cause of morbidity and mortality. However, rates of malignancy-related mortality have increased dramatically in recent years. While epidemiologic studies have suggested a possible association between statin use and a decreased risk for various malignancies, this association remains debatable given the observational nature of the available evidence and the risk for confounders.
Inflammatory bowel disease (IBD) is an immune-mediated disease of the intestinal tract, with complex pathophysiology involving genetic, environmental, microbiome, immunological and potentially other factors. Epidemiological data have provided important insights into risk factors associated with IBD, but are limited by confounding, biases and data quality, especially when pertaining to risk factors in early life. Multiomics platforms provide granular high-throughput data on numerous variables simultaneously and can be leveraged to characterize molecular pathways and risk factors for chronic diseases, such as IBD.
metaMe Health has enlisted the aid of health tech company Indegene to launch its recently-approved prescription digital therapeutic (DTx) Regulora for irritable bowel syndrome in the US. The digital health company got a green light from the FDA last November for Regulora – which delivers hypnotherapy through an Apple or Android smartphone – as a therapy for abdominal pain associated with all forms of IBS. Hypnotherapy is a recognised approach to treating pain associated with IBS, which affects 10% to 15% of all adults in the US, but until now has only been available in person through highly specialised therapists,…
CAMBRIDGE, MA — As food moves through the digestive tract, contracting muscles along the tract keep things flowing smoothly. Loss of this motility can lead to acid reflux, failure of food to move out of the stomach, or constipation. Dysmotility disorders are usually diagnosed with a catheter containing pressure transducers, which can sense contractions of the GI tract. MIT researchers have now designed a new device that could offer a cheaper and easier-to-manufacture alternative to existing diagnostics for GI dysmotility, inspired by the design of ancient Incan technology, the quipu — a set of knotted cords used to communicate information.